Chimpanzee adenoviral vectors as vaccines for outbreak pathogens

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)

(2017) Ana Maria Henao-Restrepo et al.   LANCET

Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants

(2017) Carly M. Bliss et al.   MOLECULAR THERAPY

Billion-dollar project aims to prep vaccines before epidemics hit

(2017) Declan Butler   NATURE

Nipah virus: transmission of a zoonotic paramyxovirus

(2017) Bronwyn Anne Clayton   Current Opinion in Virology

Open-label phase I clinical trial of Ad5-EBOV in Africans in China

(2017) Lihua Wu et al.   Human Vaccines & Immunotherapeutics

Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization

(2017) Christine Dahlke et al.   EBioMedicine

Ebola Virus Glycoprotein with Increased Infectivity Dominated the 2013–2016 Epidemic

(2016) William E. Diehl et al.   CELL

Human Adaptation of Ebola Virus during the West African Outbreak

(2016) Richard A. Urbanowicz et al.   CELL

A Mouse Model of Zika Virus Pathogenesis

(2016) Helen M. Lazear et al.   Cell Host & Microbe

Multivalent and Multipathogen Viral Vector Vaccines

(2016) Katharina B. Lauer et al.   Clinical and Vaccine Immunology

Viral vectors as vaccine platforms: from immunogenicity to impact

(2016) Katie J Ewer et al.   CURRENT OPINION IN IMMUNOLOGY

Ebola virus vaccines – reality or fiction?

(2016) Chad E. Mire et al.   Expert Review of Vaccines

Simian adenoviruses as vaccine vectors

(2016) Susan J Morris et al.   Future Virology

Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines

(2016) Iain D. Milligan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial

(2016) Milagritos D Tapia et al.   LANCET INFECTIOUS DISEASES

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

(2016) Selidji T. Agnandji et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

(2016) Katie Ewer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hendra virus and Nipah virus animal vaccines

(2016) Christopher C. Broder et al.   VACCINE

Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle

(2016) Pawan Dulal et al.   VACCINE

Status of vaccine research and development of vaccines for Nipah virus

(2016) Benjamin A. Satterfield et al.   VACCINE

Additives for vaccine storage to improve thermal stability of adenoviruses from hours to months

(2016) Maria Pelliccia et al.   Nature Communications

Animal models of Middle East respiratory syndrome coronavirus infection

(2015) Neeltje van Doremalen et al.   ANTIVIRAL RESEARCH

Access to Investigational Drugs: FDA Expanded Access Programs or “Right-to-Try” Legislation?

(2015) M. E. Blair Holbein et al.   CTS-Clinical and Translational Science

Stability of a Vesicular Stomatitis Virus–Vectored Ebola Vaccine

(2015) Marianne Arnemo et al.   JOURNAL OF INFECTIOUS DISEASES

Generation of a Transgenic Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease

(2015) Anurodh Shankar Agrawal et al.   JOURNAL OF VIROLOGY

Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial

(2015) Feng-Cai Zhu et al.   LANCET

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial

(2015) Angela Huttner et al.   LANCET INFECTIOUS DISEASES

How to beat the next Ebola

(2015) Declan Butler   NATURE

Establishing a Global Vaccine-Development Fund

(2015) Stanley A. Plotkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults

(2015) Caroline Ogwang et al.   Science Translational Medicine

Mapping the zoonotic niche of Lassa fever in Africa

(2015) Adrian Q. N. Mylne et al.   TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE

Evaluation of candidate vaccine approaches for MERS-CoV

(2015) Lingshu Wang et al.   Nature Communications

Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy

(2014) William Wold et al.   CURRENT GENE THERAPY

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals

(2014) Susanne H. Hodgson et al.   JOURNAL OF INFECTIOUS DISEASES

Neurovirulence and Immunogenicity of Attenuated Recombinant Vesicular Stomatitis Viruses in Nonhuman Primates

(2014) D. K. Clarke et al.   JOURNAL OF VIROLOGY

Mouse Dipeptidyl Peptidase 4 Is Not a Functional Receptor for Middle East Respiratory Syndrome Coronavirus Infection

(2014) A. S. Cockrell et al.   JOURNAL OF VIROLOGY

Severe fever with thrombocytopenia syndrome, an emerging tick-borne zoonosis

(2014) Quan Liu et al.   LANCET INFECTIOUS DISEASES

A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS

(2014) Eoghan de Barra et al.   PLoS One

Rapid generation of a mouse model for Middle East respiratory syndrome

(2014) Jincun Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins

(2014) Blair L. DeBuysscher et al.   VACCINE

Infection with MERS-CoV Causes Lethal Pneumonia in the Common Marmoset

(2014) Darryl Falzarano et al.   PLoS Pathogens

A treatment for and vaccine against the deadly Hendra and Nipah viruses

(2013) Christopher C. Broder et al.   ANTIVIRAL RESEARCH

Mice Lacking Functional STAT1 Are Highly Susceptible to Lethal Infection with Lassa Virus

(2013) N. E. Yun et al.   JOURNAL OF VIROLOGY

A decade after SARS: strategies for controlling emerging coronaviruses

(2013) Rachel L. Graham et al.   NATURE REVIEWS MICROBIOLOGY

Pneumonia from Human Coronavirus in a Macaque Model

(2013) Vincent J. Munster et al.   NEW ENGLAND JOURNAL OF MEDICINE

An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity

(2013) Juan C Zapata et al.   Virology Journal

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation

(2013) Katie J. Ewer et al.   Nature Communications

Vaccines for viral hemorrhagic fevers—progress and shortcomings

(2013) Darryl Falzarano et al.   Current Opinion in Virology

Vaccination Strategies against Highly Pathogenic Arenaviruses: The Next Steps toward Clinical Trials

(2013) Stephan Ölschläger et al.   PLoS Pathogens

Animal models for Ebola and Marburg virus infections

(2013) Eri Nakayama et al.   Frontiers in Microbiology

Type I Interferon Signaling Protects Mice From Lethal Henipavirus Infection

(2012) Kévin P. Dhondt et al.   JOURNAL OF INFECTIOUS DISEASES

Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector

(2012) Geraldine A. O’Hara et al.   JOURNAL OF INFECTIOUS DISEASES

Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia

(2012) Ali M. Zaki et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors

(2012) Susanne H. Sheehy et al.   PLoS One

A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity

(2012) Matthew D. J. Dicks et al.   PLoS One

A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years

(2012) Richard D. Antrobus et al.   PLoS One

A Hendra Virus G Glycoprotein Subunit Vaccine Protects African Green Monkeys from Nipah Virus Challenge

(2012) K. N. Bossart et al.   Science Translational Medicine

Lassa Fever in West Africa: Evidence for an Expanded Region of Endemicity

(2012) N. Sogoba et al.   Zoonoses and Public Health

Immune Responses and Lassa Virus Infection

(2012) Marion Russier et al.   Viruses-Basel

Advanced Vaccine Candidates for Lassa Fever

(2012) Igor Lukashevich   Viruses-Basel

Argentine hemorrhagic fever vaccines

(2011) Ana Ambrosio et al.   Human vaccines & immunotherapeutics

Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge

(2011) T. W. Geisbert et al.   JOURNAL OF VIROLOGY

Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors

(2011) Susanne H Sheehy et al.   MOLECULAR THERAPY

CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates

(2011) Nancy J Sullivan et al.   NATURE MEDICINE

A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge

(2011) Jackie Pallister et al.   VACCINE

Current Good Manufacturing Practice Production of an Oncolytic Recombinant Vesicular Stomatitis Viral Vector for Cancer Treatment

(2010) L.J. Ausubel et al.   HUMAN GENE THERAPY

Pathogenesis and Immune Response of Crimean-Congo Hemorrhagic Fever Virus in a STAT-1 Knockout Mouse Model

(2010) D. A. Bente et al.   JOURNAL OF VIROLOGY

Capsid-Incorporation of Antigens into Adenovirus Capsid Proteins for a Vaccine Approach

(2010) Qiana L. Matthews   MOLECULAR PHARMACEUTICS

Development of an Acute and Highly Pathogenic Nonhuman Primate Model of Nipah Virus Infection

(2010) Thomas W. Geisbert et al.   PLoS One

Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs

(2010) Xiaohong Jiang et al.   VACCINE

Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule

(2009) Nancy J. Sullivan et al.   NATURE REVIEWS MICROBIOLOGY

A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo

(2009) Craig W. Day et al.   VIROLOGY

A Neutralizing Human Monoclonal Antibody Protects against Lethal Disease in a New Ferret Model of Acute Nipah Virus Infection

(2009) Katharine N. Bossart et al.   PLoS Pathogens

Global trends in emerging infectious diseases

(2008) Kate E. Jones et al.   NATURE

A Mouse Model for Chikungunya: Young Age and Inefficient Type-I Interferon Signaling Are Risk Factors for Severe Disease

(2008) Thérèse Couderc et al.   PLoS Pathogens